Irish Journal of Medical Science (1971 -)

, Volume 187, Issue 2, pp 441–446 | Cite as

Clinical evaluation for sublingual immunotherapy with Dermatophagoides farinae drops in adult patients with allergic asthma

  • C. Zhong
  • W. Yang
  • Y. Li
  • L. Zou
  • Z. Deng
  • M. Liu
  • X. Huang
Original Article



The efficacy and safety of sublingual immunotherapy (SLIT) in house dust mite-induced allergic asthma (AA) have yet to be firmly established, especially in adult patients. Our objective is to evaluate the efficacy of SLIT with Dermatophagoides farinae drops in adult patients with AA.


One hundred and thirty-four adult patient data with house dust mite (HDM)-induced AA who had been treated for 2 years were collected. These patient data that we collected were divided into the SLIT group (n = 85) and control group (n = 49). All patients were treated with low to moderate dose of inhaled glucocorticoid and long-acting β2 agonists. Patients in the SLIT group were further treated with D. farinae drops. Clinical scores including the total asthma symptom score (TASS), total asthma medicine score (TAMS), asthma control test (ACT), and peak flow percentage (PEF%) were assessed before treatment and at yearly visits. The presence of adverse events (AEs) were recorded once a month.


Before treatment, the PEF% in the SLIT group was significantly lower than that in the control group (p < 0.05). After 2 years, both treatments were effective in the clinical scores when compared with baseline values (all p < 0.001). Meanwhile, the SLIT group showed significantly lower TASS and TAMS (all p < 0.001) and higher ACT (p < 0.001) and PEF% (p < 0.05) when compared with the control group. No severe systemic AEs were reported.


SLIT with D. farinae drops plus pharmacotherapy is more effective than routine drug treatment in adult patients with AA.


Adult patient Allergic asthma Sublingual immunotherapy 



We thank the patients for their availability in taking part in this trial.

Funding information

All financial supports for this clinical trial were provided by the Department of Science and Technology project of Wuzhou City, Guangxi Province, China (Contract No. 201202081).

Compliance with ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Yukselen A, Kendirli SG (2014) Role of immunotherapy in the treatment of allergic asthma. World J Clin Cases: WJCC 2(12):859.  10.12998/wjcc.v2.i12.859 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    The global asthma report 2014. Available at:
  3. 3.
    Masoli M, Fabian D, Holt S et al (2004) Global burden of asthma. Allergy 59:469–478CrossRefPubMedGoogle Scholar
  4. 4.
    Knudsen TB, Thomsen SF, Nolte H et al (2009) A population-based clinical study of allergic and non-allergic asthma. J Asthma 46:91–94. CrossRefPubMedGoogle Scholar
  5. 5.
    Zureik M, Neukirch C, Leynaert B et al (2002) Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community Respiratory Health Survey. BMJ 325:411–414CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Masoli M, Fabian D, Holt S et al (2004) The global burden of asthma: executive summary of the GINA dissemination committee report. Allergy 59:469–478. CrossRefPubMedGoogle Scholar
  7. 7.
    Li J, Sun B, Huang Y et al (2009) A multicentre study assessing the prevalence of sensitizations in patients with asthma and/or rhinitis in China. Allergy 64:1083–1092. CrossRefPubMedGoogle Scholar
  8. 8.
    Platts-Mills TAE, Erwin EA, Heymann PW et al (2009) Pro: the evidence for a causal role of dust mites in asthma. Am J Respir Crit Care Med 180:109–121. CrossRefPubMedGoogle Scholar
  9. 9.
    Li J, Sun B, Huang Y et al (2009) A multicentre study assessing the prevalence of sensitizations in patients with asthma and/or rhinitis in China. Allergy 64(7):1083–1092. CrossRefPubMedGoogle Scholar
  10. 10.
    Lind P, Hansen OC, Horn N (1988) The binding of mouse hybridoma and human IgE antibodies to the major fecal allergen, der p I, of Dermatophagoides pteronyssinus. Relative binding site location and species specificity studied by solid-phase inhibition assays with radiolabeled antigen. J Immunol 140(12):4256–4262PubMedGoogle Scholar
  11. 11.
    Thomas WR, Smith WA, Hales BJ et al (2002) Characterization and immunobiology of house dust mite allergens. Int Arch Allergy Immunol 129(1):1CrossRefPubMedGoogle Scholar
  12. 12.
    Yasueda H, Mita H, Yui Y et al (1989) Comparative analysis of physicochemical and immunochemical properties of the two major allergens from Dermatophagoides pteronyssinus and the corresponding allergens from Dermatophagoides farinae. Int Arch Allergy Appl Immunol 88(4):402–407CrossRefPubMedGoogle Scholar
  13. 13.
    Bousquet J, Lockey R, Malling HJ (1998) World Health Organization position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53(Suppl. 44):1–42Google Scholar
  14. 14.
    Akdis CA, Akdis M (2011) Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 127:18–27CrossRefPubMedGoogle Scholar
  15. 15.
    Akdis CA (2012) Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med 18:736–749CrossRefPubMedGoogle Scholar
  16. 16.
    Calamita Z, Saconato H, Pela AB et al (2006) Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials using the Cochrane collaboration method. Allergy 61:1162–1172. CrossRefPubMedGoogle Scholar
  17. 17.
    Compalati E, Passalacqua G, Bonini M et al (2009) The efficacy of sublingual immunotherapy for house dust mite respiratory allergy: results of a GA2LEN meta-analysis. Allergy 64:1570–1579. CrossRefPubMedGoogle Scholar
  18. 18.
    Canonica GW, Bousquet J, Casale T et al (2009) Sub-lingual immunotherapy: World Allergy Organization position paper 2009. Allergy 64(Suppl. 91):1–59. PubMedGoogle Scholar
  19. 19.
    Radulovic S, Wilson D, Calderon M et al (2011) Systematic reviews of sublingual immunotherapy (SLIT). Allergy 66:740–752. CrossRefPubMedGoogle Scholar
  20. 20.
    Global Initiative for Asthma (GINA) Executive Committee (2006) Global strategy for asthma management and prevention 1–110Google Scholar
  21. 21.
    Wang H, Lin X, Hao C et al (2006) A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 61:191–197. CrossRefPubMedGoogle Scholar
  22. 22.
    Pfaar O, Demoly P, Gerth van Wijk R et al (2014) Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper. Allergy 69(7):854–867. CrossRefPubMedGoogle Scholar
  23. 23.
    Schlosser RJ, Smith TL, Mace J et al (2016) Asthma quality of life and control after sinus surgery in patients with chronic rhinosinusitis. Allergy.
  24. 24.
    Abramson MJ, Puy RM, Weiner JM (1995) Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 151:969–974. PubMedGoogle Scholar
  25. 25.
    Ross RN, Nelson HS, Finegold I (2000) Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther 22:329–341. CrossRefPubMedGoogle Scholar
  26. 26.
    Pifferi M, Baldini G, Marrazzini G et al (2002) Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy 57:785–790CrossRefPubMedGoogle Scholar
  27. 27.
    Basomba A, Tabar AI, de Rojas DH et al (2002) Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients. J Allergy Clin Immunol 109:943–948CrossRefPubMedGoogle Scholar
  28. 28.
    García-Robaina JC, Sánchez I, de la Torre F et al (2006) Successful management of mite-allergicasthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 118:1026–1032. CrossRefPubMedGoogle Scholar
  29. 29.
    Wang L, Yin J, Fadel R et al (2014) House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy 69(9):1181–1188. CrossRefPubMedGoogle Scholar
  30. 30.
    Mosbech H, Deckelmann R, De Blay F et al (2014) Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 134:568–575. CrossRefPubMedGoogle Scholar
  31. 31.
    Virchow JC (2016) Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma. JAMA 315:1715–1725. CrossRefPubMedGoogle Scholar
  32. 32.
    Shao J, Cui YX, Zheng YF et al (2014) Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis. Am J Rhinol Allergy 28(2):131. CrossRefPubMedGoogle Scholar
  33. 33.
    Li P, Li Q, Huang Z et al (2014) Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases[C]. Int Forum Allergy Rhinol.
  34. 34.
    Keles S, Karakoc-Aydiner E, Ozen A et al (2011) A novel approach inallergen-specific immunotherapy: combination of sublingual and subcutaneous routes. J Allergy Clin Immunol 128:808–815. CrossRefPubMedGoogle Scholar
  35. 35.
    Dahl R, Stender A, Rak S (2006) Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 61:185–190. CrossRefPubMedGoogle Scholar
  36. 36.
    Moral A, Moreno V, Girón F et al (2016) Adverse reactions and tolerability of high-dose sublingual allergen immunotherapy. J Asthma Allergy 9:129–133. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2017

Authors and Affiliations

  • C. Zhong
    • 1
  • W. Yang
    • 1
  • Y. Li
    • 1
  • L. Zou
    • 1
  • Z. Deng
    • 1
  • M. Liu
    • 1
  • X. Huang
    • 1
  1. 1.Department of RespiratoryWuzhou Red Cross HospitalWuzhouChina

Personalised recommendations